Clinical Trial Update: Nucleus Hybrid L24 Extended Duration Post Approval Study [NA]

View source ↗

Summary

Clinical trial update for an extended duration post-approval study related to hearing loss; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hearing Loss

Drugs mentioned

• Nucleus Hybrid L24

Snippet

Sponsor: Cochlear | Conditions: Hearing Loss | NA | Status: COMPLETED | Results posted: 2021-11-30